Our resources

Peer-Reviewed Papers

Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
Trial Analysis
Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
READ MORE →
 Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer
Trial Analysis
Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer
READ MORE →
 Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit
Trial Analysis
Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit
READ MORE →
 The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
Trial Analysis
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
READ MORE →
 An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
Trial Analysis
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
READ MORE →